Somewhat Positive News Coverage Somewhat Unlikely to Impact Opko Health (OPK) Share Price

Share on StockTwits

News articles about Opko Health (NASDAQ:OPK) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Opko Health earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.8254717820947 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research analysts have recently issued reports on OPK shares. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, May 12th. Zacks Investment Research cut shares of Opko Health from a “buy” rating to a “hold” rating in a report on Friday, May 25th. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price objective on shares of Opko Health in a report on Tuesday, August 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $10.95.

Shares of NASDAQ:OPK opened at $5.59 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.90. The company has a market capitalization of $3.25 billion, a P/E ratio of -19.28 and a beta of 2.09. Opko Health has a 52 week low of $2.66 and a 52 week high of $7.24.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.06. The business had revenue of $263.69 million during the quarter, compared to the consensus estimate of $260.37 million. Opko Health had a negative net margin of 31.73% and a negative return on equity of 9.32%. research analysts expect that Opko Health will post -0.23 earnings per share for the current year.

In related news, CEO Phillip Md Et Al Frost bought 10,000 shares of the business’s stock in a transaction on Wednesday, September 5th. The stock was bought at an average price of $5.79 per share, for a total transaction of $57,900.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $17,769,226.29. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders acquired 344,519 shares of company stock valued at $1,790,769. Insiders own 42.74% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Read More: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with's FREE daily email newsletter.

Leave a Reply